Always a risk....but perhaps less so now that FDA has approved the trial.

I wouldn't waste your money on the article.

Resverlogix's (TSE:RVX) apabetalone for reducing cardiovascular disease (CVD) event risk has experts debating whether its targeting of diabetic patients with impaired kidney function could backfire in a Phase III trial, reducing its approval prospects

That is factually incorrect. There is no targeting of diabetic patients with impaired kidney function in Betonmace. 

The inclusion criteria for the trial do not specify impaired renal function at baseline.

Therfore, I'd be skeptical of the entire article.

bfw